We report a patient with Philadelphia (Ph)-positive, BCR-ABL rearrangement positive, chronic myeloid leukemia (CML) with a prolonged chronic phase of 24 years who was first prescribed alpha-2 interferon 22 years after initial diagnosis. This therapy was tolerated poorly on account of thrombocytopenia, but an eventual major cytogenetic response was followed soon afterwards by transformation to terminal acute myeloid leukemia (AML). Cytogenetic studies indicated that the transformed myeloblasts were karyotypically normal and Ph negative. Although polymerase chain reaction (PCR) analysis of total leukemic mRNA remained BCR-ABL positive, other molecular studies, including Southern blotting and fluorescent in situ hybridization (FISH) analyses, showed that myeloblasts were BCR-ABL rearrangement negative. PCR-based clonality studies using an X-chromosome-linked restriction fragment polymorphism within the phosphoglycerate kinase gene (PGK 1 ) further showed that the Ph-negative blast cells had a different clonal origin from the Ph-positive clone of chronic phase. We suggest that cases of underlying Ph-negative leukemic transformation in Ph-positive CML warrant further study and should be considered for trial of intensive remission induction therapy as appropriate for acute leukemia.
Introduction
Chronic myeloid leukemia (CML) is a malignant clonal disorder associated with a molecular rearrangement between the ABL and BCR genes from chromosome 9 and 22, respectively. 1, 2 It is a progressive disease that transforms to an acclerated and/or blast phase after a chronic phase of 5 years median duration, although rare patients showing an extremely protracted chronic phase survival of more than 20 years are reported. 3 During transformation, more aggressive leukemic clones evolve from cells affected by the BCR-ABL rearrangement.
In about 90% of CML cases, leukemic cells are characterized cytogenetically by the Philadelphia or Ph chromosome, a deleted chromosome 22 which represents one product of a reciprocal translocation, t(9;22)(q34;q11) caused by the BCR-ABL rearrangement. The remaining 10% of cases show more complex rearrangements, sometimes camouflaged by a normal karyotype, and involve chromosomal sites additional to BCR and ABL. 2, 4 Cytogenetic abnormalities in addition to the t(9,22) or its more complex variants are rare in chronic phase CML, but frequently accumulate during tran-sition to acute phase. These additional changes are considered prognostic for terminal disease. 5 We report hematological and molecular features of a CML patient who showed a prolonged Ph-positive chronic phase of 24 years. The patient was treated with alpha-2 interferon (␣-IFN), but after achieving cytogenetic remission her disease rapidly evolved into an acute myeloid leukemia (AML). Cytogenetic and molecular studies showed that the leukemia blast cells were karyotypically normal, BCR-ABL rearrangement negative, and derived from a different clone than leukemia cells of chronic phase CML.
Case report
A 32-year-old female presented to a peripheral hospital in 1972 with excessive tiredness, menorrhagia and weight loss. Examination revealed moderate splenomegaly and a blood count showed hemoglobin 119 g/l, white cell count 182 × 10 9 /l, bands 25%, polymorphs 40%, lymphocytes 1%, eosinophils 1%, basophils 4%, blasts 3%, promyelocytes 2%, myelocytes 13%, metamyelocytes 11% and platelets 473 × 10 9 /l. Bone marrow examination was consistent with chronic phase CML. Cytogenetic and neutrophil alkaline phosphatase analyses were not performed at this time. She was commenced on busulphan, which was successfully discontinued after 2 to 3 years. She remained well and continued working as a charge nurse. In 1991 and between 1993 and 1994, she required two additional 3-month courses of busulphan for control of her white count. In October 1994 she was referred to the Clinical Hematology Unit, Christchurch Hospital, for molecular and cytogenetic assessment and for consideration of alpha-2 interferon (␣-IFN) treatment. Chronic phase CML was confirmed, with 100% Ph-positive cells, and molecular analysis revealed a b3/a2 BCR/ABL rearrangement. Treatment with ␣-IFN (Roferon; Roche, New Zealand) was commenced at a dose of 3 mega-units (MU)/day, increasing to a maximal dose of 9 MU/day. The patient failed to tolerate full-dose ␣-IFN on account of thrombocytopenia, but a variable dosage schedule was initiated, and she eventually developed a minor and then a major cytogenetic response. Her hematological response to therapy is charted in Figure 1 .
In May 1996, the patient's white cell count increased and blast cells appeared in the peripheral blood. A marrow examination in July 1996 showed 8% blasts, and cytogenetic analysis showed that all metaphase cells analyzed (n = 50) were Phnegative. A repeat assessment was arranged, but in August 1996 clinical symptoms of fever, malaise, and tender splenomegaly, in combination with a rapidly rising WCC and increased blast cells, indicated acute myeloblastic transformation. Bone marrow examination showed 28% blasts that
Figure 1
Daily or weekly (wk) interferon dosage (a) and blood count (b) at various time points during the period of interferon therapy. MU, mega-units; WBC, white blood count (); PLTS, platelet count (᭹). expressed CD34 and the myeloid antigens CD13 and CD33. Repeat cytogenetic analysis of this sample confirmed 49/50 metaphase cells to be Ph-negative. She was treated palliatively and died 2 weeks later.
Cytogenetic and FISH analyses
Cytogenetic studies were not performed when the patient was first diagnosed with CML in 1972. Twenty-two years later, in October 1994, all 20 leukemic metaphase cells analyzed showed the standard Ph-positive karyotype 46,XX, t(9;22)(q34;q11). In June 1995, following ␣-IFN treatment, a subpopulation of karyotypically normal, Ph-negative cells (6/14 analyzed) appeared in the bone marrow. FISH studies of interphase and metaphase cells using digoxygenin-labelled 5Ј BCR (BCRH1), and biotin-labelled 3Ј ABL (cosABL8) cosmid probes showed signal patterns consistent with this finding. Using methods previously described, 6 about one-third of cells (95/274 interphase; 26/72 metaphase) showed four distinct and separate fluorescent signals, two red and two green, indicating that those cells lacked the BCR-ABL hybrid gene (Figure 2a ). Karyotype studies in September 1995 showed an increase in the proportion of Ph-negative cells to 84% (16/19) , whereas FISH studies showed approximately equal numbers of BCR-ABL-positive (89) and -negative (93) interphase cells. Five months later, in February 1996, cytogenetic analysis showed that Ph-positive leukemic cells again predominated (37/50 cells analyzed) indicating relapse of CML. In July 1996, when hematological and clinical evaluation suggested an accelerated disease phase, all G-banded metaphase cells analyzed were Ph-negative. FISH studies confirmed a higher incidence of BCR-ABL negative metaphase cells (98/113), but also demonstrated that a minor population of Ph-positive metaphases was still present (15/113). Initial analysis of the numbers of BCR-ABL-positive and -negative interphase nuclei in the latter sample was, as in the earlier samples, non-discriminatory for cell size. However, on closer inspection it was apparent that many of the BCR-ABL-positive cells were morphologically smaller than the much larger BCR-ABL-negative nuclei. Results of selective analysis of small interphase nuclei vs larger blastic nuclei showed clearly that the latter were predominantly BCR-ABL rearrangement negative (Figure 2a and data not shown) . In August 1996, when 
RT-PCR and Southern blot analyses
Southern blot analysis 7 of BglII-digested leukemic DNA from the October 1994 BM showed an abnormal fragment of approximately 9 kb using a 5Ј-M-Bcr probe, confirming rearrangement within M-Bcr of the BCR gene (Figure 2b ). Leukemic DNA from the August 1996 BM showed a rearranged BglII fragment identical in size to that of the earlier sample, but much fainter in intensity (Figure 2b) . Analysis of RT-PCR amplified leukemic cell cDNA 8 determined that the b3/a2 BCR/ABL fusion transcript was present through all disease stages (Figure 2c ). These combined results are consistent with infiltration by a predominant BCR-ABL-negative clone of blast cells at disease transformation, and persistence of small numbers of residual BCR-ABL-positive cells.
Clonality studies
PCR analysis of the PGK 1 gene was performed essentially according to Gilliland et al. 9 Heterozygosity for a known BstXI polymorphic site within the first exon of the PGK 1 gene was first established by digestion of a PCR-amplified segment containing this region from leukemic cells. Loss of one BstXI allelomorph in the October 1994 BM sample after HpaII predigestion confirmed that the patient's Ph-positive leukemia was monoclonal in origin (Figure 2d ). In contrast, both BstXI alleles were retained in leukemic BM DNA from the accelerated phase (August 1996), when Ph-negative, BCR-ABL blast cells predominated (Figure 2d ). This result is evidence that two or more leukemic clones were present in the BM at that time, with different clones showing random inactivation of the X-chromosome.
Discussion
Our studies provide the first descriptive evidence that an apparent transition to blast crisis in CML may mask a clonally unrelated AML. Blast cells from the accelerated phase in our patient were karyotypically normal, and FISH and Southern blot studies eliminated a possible submicroscopic BCR-ABL rearrangement. Clonality studies using a known restriction enzyme polymorphism in the X-linked PGK gene established that leukemic cells present during the patient's terminal disease phase were clonally unrelated to the BCR-ABL-positive leukemia, and had originated from a different hematopoietic progenitor cell mutation.
For patients with Ph-positive CML, ␣-IFN has emerged as an effective treatment when allogeneic marrow transplantation is not possible. 10 However, there is increasing evidence that new cytogenetic or malignant disorders may arise in patients undergoing ␣-IFN therapy for CML or other conditions such as hairy cell leukemia and viral hepatitis. [11] [12] [13] To our knowledge, only one other case of Ph-negative, BCR-ABL-negative AML arising after busulphan and ␣-IFN treatment for Ph-positive CML has been described, but the clonal origin of the second leukemia was not demonstrated. 14 In that case the blast cells were karyotypically abnormal, and showed trisomy for chromosomes 8 and 11.
The exact mechanism by which ␣-IFN-induced remission occurs is presently unknown. Hematological features of a recently developed murine model which carries a targeted mutation for an interferon consensus sequence binding protein (ICSBP) points to a potential regulatory role for ␣-IFN in proliferation and differentiation of hematopoietic progenitor cells. 15 ␣-IFN treatment clearly suppressed the Ph-positive clone in our patient, but in doing so may have cleared the environment for, and possibly activated the proliferative capacity of, a new or previously silent leukemic clone. The alkylating agent busulphan has been associated with a high clinical incidence of aplastic anemia and myelodysplasia, 16, 17 and increased incidence of DNA damage in mammalian cells in vitro. 18 This agent was also associated with damage, over time, to stem cell proliferative potential in cats. 19 It is possible that busulphan treatment during the early years of our patient's prolonged survival CML provided a proliferatively unstable, if dormant, stem cell pool which the ␣-IFN therapy then activated. We suggest that cases of leukemic transformation of CML in similar settings warrant further study and should be considered for conventional AML induction therapy.
